Sign in

CMMB on Nasdaq

Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. is a pharmaceutical preparations company based in Tel Aviv, listed on Nasdaq (CMMB).1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$9.0MNet income, fiscal 20252

Compare with another stock.

  • TickerCMMB on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersL31
  • Incorporated inIsrael3
  • Business addressKiryat Atidim, Building 7, Tel Aviv3
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-72.9%Return on equity2
-$11.1MFree cash flow2

Financial statements

Operating income452-$112.0M in 2025+759% since 2018
-$150.0M-$100.0M-$50.0M02018: -$13.0M-$13.0M20182024: -$103.0M-$103.0M2024+690%2025: -$112.0M-$112.0M2025+9%
Net income678952-$9.0M in 2025−35% since 2018
-$30.0M-$20.0M-$10.0M02018: -$13.8M-$13.8M20182019: -$27.1M-$27.1M2019+97%2020: -$6.0M-$6.0M2020−78%2021: -$12.5M-$12.5M2021+110%2022: -$27.6M-$27.6M2022+122%2023: -$24.2M-$24.2M2023−12%2024: -$13.9M-$13.9M2024−42%2025: -$9.0M-$9.0M2025−35%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Research and development$5.8M$11.3M$18.4M
Total operating expenses$9.6M$14.7M$25.5M
Financing income, net-$572.0K-$794.0K-$1.2M
Loss before income taxes$9.0M$13.9M$24.2M
Income Tax expenses$0$0$0
Net loss for the year$9.0M$13.9M$24.2M
Basic loss per Ordinary Share$0.02$0.04$0.10
Diluted loss per Ordinary Share$0.02$0.04$0.10
Weighted average number of Ordinary Shares outstanding, basic510.2M shares359.0M shares235.0M shares
Weighted average number of Ordinary Shares outstanding, diluted510.2M shares359.0M shares235.0M shares
General and administrative$3.7M$3.4M$7.1M

Compare Chemomab Therapeutics Ltd. with another company

Corporate structure

Chemomab Therapeutics Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Chemomab Therapeutics Ltd.

  • Chemomab Therapeutics Ltd. L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Chemomab Therapeutics Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$487.0K2 Dec 31, 2025$529.0K2 Dec 31, 2024−7.9%
Accumulated depreciation$311.0K2 Dec 31, 2025$279.0K2 Dec 31, 2024+11.5%
Property and equipment, net$176.0K2 Dec 31, 2025$250.0K2 Dec 31, 2024−29.6%
Operating-lease assets (leased space)$02 Dec 31, 2025$289.0K2 Dec 31, 2024−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.6M2 Dec 31, 2025$6.1M2 Dec 31, 2024+24.6%

Leadership

Who has led Chemomab Therapeutics Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Frank Haluska2020
  2. Neil Harris Cohen2021
  3. George Adi Mor2021
  4. Dale R. Pfost2021–2022

Chief financial officer

  1. Stephen J. Dipalma2020
  2. Andrew Fine2021
  3. Sigal Fatal2021
  4. Donald Marvin2021–2022

Chief operating officer

  1. Donald Marvin2021–2022
2025
Board members and other officers (27)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorAdi Mor named Aug 9, 202445
  • Executive OfficerSigal Fattal named Aug 9, 202445

Former names

  • Anchiano Therapeutics Ltd.Sep 28, 2018 to Mar 17, 20213
  • BioCancell Ltd.Nov 7, 2011 to Nov 3, 20153

Timeline

  1. Jun 16, 20238-K Executive or director change46
  2. Jun 5, 20238-K Executive or director change; Regulation FD disclosure47
  3. May 11, 20238-K Results of operations48
  4. Feb 21, 20238-K Results of operations49
  5. Feb 21, 20238-K Other events50
  6. Jan 11, 20238-K Regulation FD disclosure51
  7. Jan 3, 20238-K Other events52
  8. Nov 29, 20228-K Financial statements and exhibits53
  9. Nov 16, 20228-K Other events54
  10. Nov 14, 20228-K Executive or director change; Regulation FD disclosure55
  11. Aug 12, 20228-K Results of operations56
  12. Jun 21, 20228-K Financial statements and exhibits57
  13. Nov 4, 2021New chief executive Dale R. Pfost becomes CEO16
  14. Mar 25, 2021New chief executive George Adi Mor becomes CEO15
  15. Mar 11, 2021New chief executive Neil Harris Cohen becomes CEO14
  16. Jan 2, 2020New chief executive Frank Haluska becomes CEO17

Calendar

Coming up

  1. Oct 22, 2026Reports results for the quarter ending Sep/202658

When it reported results

  1. May 11, 2023Reported quarterly or annual results48
  2. Feb 21, 2023Reported quarterly or annual results49
  3. Aug 12, 2022Reported quarterly or annual results56
  4. May 12, 2022Reported quarterly or annual results59
  5. Mar 9, 2022Reported quarterly or annual results60
  6. Nov 12, 2021Reported quarterly or annual results61

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

163 filings to the SEC since October 2021: 5 annual reports, 5 quarterly reports, 26 major events, 41 insider forms, 21 large holders, 1 private raises, 64 other. The latest 20:

  1. Sep 30, 20266-K EDGAR
  2. Sep 9, 2026SCHEDULE 13D/A EDGAR
  3. Sep 1, 20264 EDGAR
  4. Aug 19, 20266-K EDGAR
  5. Aug 13, 2026SCHEDULE 13G EDGAR
  6. Aug 10, 2026SCHEDULE 13G/A EDGAR
  7. Jul 16, 2026SCHEDULE 13D EDGAR
  8. Jul 8, 20266-K EDGAR
  9. Jun 3, 20263 EDGAR
  10. Jun 2, 20266-K EDGAR
  11. Jun 1, 20264 EDGAR
  12. May 14, 20266-K EDGAR
  13. May 6, 20266-K EDGAR
  14. Apr 28, 20266-K EDGAR
  15. Apr 10, 20263 EDGAR
  16. Apr 10, 20263 EDGAR
  17. Apr 10, 20263 EDGAR
  18. Apr 10, 20263 EDGAR
  19. Apr 10, 20263 EDGAR
  20. Apr 10, 20263 EDGAR

The 163 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 10 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 28, 2026Cohen Neil HarrisDirectorSale1,000$2.80$2.8KForm 4
Aug 27, 2026Cohen Neil HarrisDirectorSale1,304$2.85$3.7KForm 4
May 29, 2026Mor George AdiChief Executive OfficerBuy9,804$2.07$20.2KForm 4
Jan 3, 2023Mor George AdiChief Executive OfficerSale13,800$5.03$69.4KForm 4
Jan 3, 2023OrbiMed Israel BioFund GP Limited Partnership10% ownerSale336,900$3.58$1.2MForm 4
Nov 16, 2022Cohen Neil HarrisDirectorSale2,409$2.00$4.8KForm 4
Nov 16, 2022Mor George AdiChief Executive OfficerSale582,023$2.08$1.2MForm 4
May 24, 2022Maryles Joel MichaelDirectorBuy433$2.88$1.2KForm 4
May 18, 2022Cohen Neil HarrisDirectorBuy2,000$3.19$6.4KForm 4
Mar 18, 2022Maryles Joel MichaelDirectorBuy1,000$4.34$4.3KForm 4
Mar 16, 2022Marvin DonaldExecutive VP, CFO & COOBuy500$3.27$1.6KForm 4
Mar 14, 2022Marvin DonaldExecutive VP, CFO & COOBuy1,250$4.04$5.0KForm 4
Mar 14, 2022Pfost Dale RChief Executive OfficerBuy2,500$3.98$9.9KForm 4
Mar 14, 2022Cohen Neil HarrisDirectorBuy6,000$4.35$26.1KForm 4
Mar 11, 2022Darvish NissimDirectorBuy1,200$4.28$5.1KForm 4
Dec 6, 2021Cohen Neil HarrisDirectorBuy2,000$7.43$14.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 29, 2024Raised $10 million in a private offering of equity Form D: 10 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC95,311$154.4K0.0%+31,129
ADAR1 Capital Management, LLC80,000$129.6K0.0%No change
Kestra Private Wealth Services, LLC61,710$100.0K0.0%No change
Ikarian Capital, LLC51,793$83.9K0.0%No change
Rhumbline Advisers30,529$49.5K0.0%+12,163
XTX Topco Ltd15,987$25.9K0.0%−2,642
Philadelphia Investment Partners, LLC15,000$24.3K0.0%+6,800
Lido Advisors, LLC14,341$23.2K0.0%New
Bnp Paribas Financial Markets6,805$11.0K0.0%−1,620
GAMMA Investing LLC4,740$7.7K0.0%−2,839
Morgan Stanley3,575$5.8K0.0%−1,000
SBI Securities Co., Ltd.34$550.0%+6
Caitong International Asset Management Co., Ltd8$130.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Chemomab Therapeutics Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARChemomab Therapeutics Ltd.1
  • CIK0001534248
  • Employer ID (EIN)81-36767731
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company71
  • Incorporated inIsrael71
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressKiryat Atidim, Building 7, Tel Aviv, Israel1
  • Phone972-77-331-01561
  • Shares outstanding575,381,320 shares as of Dec 31, 202571
  • AuditorSomekh Chaikin, Tel Aviv, Israel PCAOB ID 1057; no auditor attestation of internal control over financial reporting71
  • On EDGAR sinceNov 7, 20111
  • Filings360 in all: 6-K (64), 8-K (46), 3 (44), 4 (39), SC 13D/A (17), CORRESP (12), 10-Q (10), UPLOAD (10)1
    All 52 form types

    EFFECT (9), 425 (7), SCHEDULE 13G/A (6), 20-F (5), DEF 14A (5), S-1/A (5), S-8 (5), SC 13G (5), 10-K (4), 424B3 (4), 8-K/A (4), F-1/A (4), PRE 14A (4), SC 13D (4), 424B5 (3), DEFA14A (3), DRS (3), SC 13G/A (3), D (2), DRS/A (2), F-3 (2), F-4/A (2), POS AM (2), S-3 (2), S-4 (2), SCHEDULE 13D/A (2), SCHEDULE 13G (2), 144 (1), 15-15D (1), 20-F/A (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), CT ORDER (1), DRSLTR (1), F-1 (1), F-3/A (1), F-4 (1), RW (1), S-1 (1), S-4/A (1), S-8 POS (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (20-F) Mar 23, 2026
    Quarterly report (10-Q) May 11, 2023
    Proxy statement (DEF 14A) Apr 28, 2022
    Latest 8-K (8-K) Jun 16, 2023

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing eighty (80) ordinary shares, no par value per shareCMMBNasdaq
Ordinary shares, no par-valueNANasdaq

From the cover page of the 20-F filed Mar 23, 2026 (Section 12(b) of the Exchange Act).71

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
    SEC EDGAROther events
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71